Consolidation Accelerates in Animal Health — and This Time It’s Different
The rumor mill prepared us for this, but Cencora’s decision to merge MWI Animal Health with private equity backed Covetrus is not just another headline. For MWI and Covetrus reps, competing distributors, and manufacturers who rely on the channel, this is a structural shift in how animal health products will be sold, supported and negotiated in the years ahead.
Implications for MWI/Covetrus DSRs
First, portfolios get broader. A combined MWI and Covetrus brings distribution, PIMS, e-commerce, pharmacy, compounding, and data under one umbrella. That creates a more powerful story in front of independent practices and enterprise groups. Reps who can articulate bundled value across ordering, inventory, online pharmacy, technology and analytics will have a more favorable seat at the table.
Second, expectations will rise. Larger strategic accounts will likely see expanded cross-selling targets. Territory alignments may shift. Compensation structures could evolve to reflect technology and pharmacy penetration, not just sales volume. In short, the role of the distributor rep becomes broader, and reflects that more of a business partner.
Integration also brings uncertainty. Overlapping territories and duplicate roles will exist. Historically, disruption inside large organizations creates windows of opportunity for high performers who can adapt and change as the new organization evolves.
Implications for competing distributors
A combined MWI and Covetrus will command enormous purchasing leverage with manufacturers. That can translate into aggressive pricing programs, private label expansion and preferred positioning across integrated technology channels. Competing national distributors will need to match that intensity or double down on what makes them different. Service depth, specialty expertise, independence, flexible contract structures and faster decision-making may become the primary selling points.
Regional distributors and niche players may find opportunity in positioning themselves as neutral partners. With significant consolidation, some practices will worry about reduced options. Practices that currently maintain two distributor relationships may lean even harder into diversification to preserve negotiating leverage.
Implications for manufacturers
A larger, more vertically integrated channel partner means broader reach and potentially better execution. It also means greater concentration of volume in fewer hands. Rebate pressure is unlikely to ease. Private label competition will intensify. Marketing dollars may face higher scrutiny as integrated data visibility expands. The question manufacturers must answer is whether this combined entity becomes indispensable to growth or simply more formidable in negotiation. The answer is probably both.
For field sales teams representing manufacturers, alignment with distributor reps becomes even more critical. Access to key accounts may increasingly flow through integrated distribution and technology relationships. Joint planning, data sharing and coordinated account strategy will matter more than ever.
Stepping back, this merger underscores a broader reality. Distribution is no longer just about logistics, it’s about data, workflow control, digital storefronts and ownership of prescription channels. Scale is now measured as much by software penetration and analytics capability as by warehouse footprint.
The veterinary market is adjusting to softer visit growth, price sensitivity and operational strain inside practices. In slower growth environments, scale and integration become defensive strategies. Capital invested in this sector expects returns. When organic growth moderates, consolidation accelerates. Expect more of it across the veterinary channel over the next 12-18 months.
Last, adaptability will define future success, regardless of where you work. Think differently, listen more closely to both internal communications and customer perceptions, adopt tools that help you go faster and meet the needs of your customers better, and you’ll survive and likely thrive.
This is unlikely to be the last move we see in 2026. In fact, it may prove to be the catalyst for additional realignment across not just animal health distribution channels, but other sectors of animal health as well.
Hang tight. The next six months will be very interesting!
1. The role of the rep is expanding
With distribution, PIMS, e-commerce, pharmacy and data under one umbrella, sales reps will be expected to sell integrated solutions — not just products. Cross-selling, technology adoption and strategic account planning will carry more weight in compensation and performance expectations.
2. Competitive pressure will intensify
The combined entity gains significant purchasing leverage and pricing power. National competitors must match that scale or differentiate through service, specialty expertise and flexibility. Regional distributors may benefit as practices seek diversification to preserve negotiating leverage.
3. Manufacturers face greater concentration
A more vertically integrated partner offers broader reach — but also tighter rebate scrutiny, stronger private-label competition and fewer major channel options. Alignment between manufacturer reps and distributor teams will become even more critical to maintain access and influence.
Image Credit:
istockphoto.com/sturti
istockphoto.com/Sean Anthony Eddy
